Browsing tag:

mantle cell lymphoma


Exciting new was recently revealed from Pharmacyclics, when it was announced that the New Drug Application for Ibrutinib was placed on a priority basis by the FDA. This NDA for Ibrutinib is applicable in two different oncology indications. The first indication for Ibrutinib is for patients with mantle cell lymphoma (MCL) who have received prior[…]

Read More

Lenalidomide created quite a stir on Wall Street on July 11, 2013 when shares of Celgene’s Revlimid, the brand name of Lenalidomide, soared. The frenzy occurred after Celgene released data from the Phase 3 study of Lenalidomide, revealing¬† the great success of this blood cancer drug. Lenalidomide proved in Phase 3 studies to effectively halt[…]

Read More

The World Health Organization has predicted over 20 million new cancer cases in 2015 worldwide. This seemingly unbelievable number is not only astonishing; it is also a dire warning from the WHO. With the future onslaught of patients needing cancer care and treatments, the WHO has been urging researchers to continue to develop new products[…]

Read More

This website uses cookies. By using our site, you agree to our terms of service